Aravive

Aravive, Batiraxcept, layoff, Aravive layoff, Ovarian cancer

Aravive’s Desperate Bid for Survival: Drastic Layoffs as Company Nears Liquidation

Anika Sharma

Aravive, a biotech company, is currently facing a critical juncture as it grapples with the aftermath of a disappointing Phase ...

Batiraxcept Does Not Improve Survival in Ovarian Cancer Patients

PFS in Patients with Platinum-Resistant Ovarian Cancer Is Not Improved by Batiraxcept

SG Tylor

Source – Aravive The Phase III AXLerate-OC trial (NCT04300140) assessing the combination of batiraxcept with paclitaxel has not met its ...